Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05649137 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
A Phase 3 study of Obesity and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 512
- Enrollment target
- 20
- Study locations
NCT05649137: Completed Phase 3 study of Obesity and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S.
NCT05649137 is a Phase 3 study of Obesity and Diabetes Mellitus, Type 2 that has completed, run by Novo Nordisk A/S. The registered enrollment target is 512 participants, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05649137, a Phase 3 study of Obesity and Diabetes Mellitus, Type 2, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 512 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants are more likely (4 out of 5) to get semaglutide than the "dummy" medicine. The study medicine will be injected briefly, under skin, with a thin needle, typically in the stomach, thighs, or upper arms. After receiving first dose, the dose of semaglutide will be gradually increased until reaching the target dose. The study will last for about 1.5 years
Primary Outcome
Relative change in body weight from baseline (week 0) to end of treatment (week 72) is presented.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
Study Locations (20)
Texas
- Amarillo Med Spec LLP - Amarillo
- Elligo Clin Res Centre - Austin
- Velocity Clin Res, Dallas - Dallas
- UT Southwestern Medical Center - Lingvay - Dallas
- PlanIt Research, PLLC - Houston
- DCOL Ctr for Clin Res - Longview
Florida
- ARS- Deland CRU - DeLand
- Jacksonville Ctr for Clin Res - Jacksonville
- Florida Inst For Clin Res LLC - Orlando
- Oviedo Medical Research, LLC - Oviedo
California
- John Muir Physicians Network - Concord
- Velocity Clinical Research Westlake - Los Angeles
- Diablo Clinical Research, Inc. - Walnut Creek
Alabama
- Univ of Alabama Birmingham - Birmingham
- Chambliss Clinical Trials, LLC - Montgomery
North Carolina
- University of North Carolina - Chapel Hill
- PharmQuest Life Sciences LLC - Greensboro
Colorado
- New West Physicians PC - Golden
Georgia
- Hope Clin Res & Wellness - Conyers
New York
- AMC Community Endocrinology - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2023-01-04 |
| Est. Completion | 2024-12-13 |
| Phase | Phase 3 |
What the finished NCT05649137 record still lists
NCT05649137 is an interventional study that assigns participants to a tested intervention. The registered 512 participants enrollment target is mid-sized for trials with a published cap, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (37% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05649137 names 20 study sites across 8 states, led by Texas, Florida, California.
Frequently Asked Questions
What is clinical trial NCT05649137 about?
NCT05649137 is a clinical study titled "A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight". This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medici...
What is the current status of trial NCT05649137?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 512 participants. The study started on 2023-01-04. Estimated completion is 2024-12-13.
What conditions does trial NCT05649137 study?
This clinical trial studies the following conditions: Obesity, Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT05649137?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT05649137?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05649137 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05649137's enrollment target sits among peer trials
512 132nd of 1053 higher than 922 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
- NCT05337410 · 512 participants · NA
YES: Innovative Discussion for Engagement, Achievement, and Service
- NCT06096259 · 512 participants · Phase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI